MedTrace Logo

The Gut Microbiome and Immunotherapy Response in Solid Cancers

NCT06050733 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2025-12-19

No results posted yet for this study

Summary

The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.

Conditions

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • Melinda Sheffield-Moore, PhD · University of Texas

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06050733 on ClinicalTrials.gov